Physician profile
James K Warren
NPI 1942296769
$2,777.22
in general payments reported to CMS, 2019-2025
19 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $68.46 · 2021: $336 · 2022: $525 · 2023: $386 · 2024: $313 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $783.04 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $730.54 | 2019 | |
| Boston Scientific Corporation | $446.24 | 2019-2024 | Intracept |
| Astrazeneca Pharmaceuticals LP | $262.53 | 2019-2024 | Brilinta, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $194.07 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $160.51 | 2022-2025 | Verquvo |
| Abbott Laboratories | $144.28 | 2022-2023 | Proclaim |
| Janssen Pharmaceuticals, INC | $134.34 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $98.49 | 2019-2025 | |
| Cvrx, INC. | $81.29 | 2022-2025 | Barostim Neo System |
| Astellas Pharma US INC | $75.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $72.29 | 2025 | Camzyos |
| Amarin Pharma, INC. | $66.66 | 2020-2021 | |
| Relievant Medsystems, INC. | $60.79 | 2023 | Intracept |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.90 | 2022-2024 | Jardiance |
| Amgen INC. | $53.64 | 2022-2024 | Repatha |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $52.88 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $46.36 | 2022-2023 | Onpattro |
| Stimwave Technologies Incorporated | $19.89 | 2019 | |
| Curonix LLC | $19.52 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.